About Senomyx (NASDAQ:SNMX)
Senomyx, Inc. is focused on using taste receptor technologies to discover, develop and commercialize flavor ingredients for the packaged food, beverage and ingredient supply industries. The Company operates through development and commercialization of flavor ingredients segment. It is engaged in the discovery, development and/or commercialization of flavor ingredients through over five programs. The Sweet Taste Program is focused on developing flavor ingredients or discovering natural sweeteners. The Savory Flavor Program is focused at flavor ingredients to be used in product categories, such as ready meals, sauces, soups and snack foods. The Bitter Blocker Program is focused on flavor ingredients used in products that contain bitter tastants. The Cooling Taste Program is focused at flavor ingredients used in products that consist of cooling agents. The salt taste modifier program is focused on reduction of the level of salt contained in packaged food and beverage products.
Industry, Sector and Symbol:
- Sector: Consumer Staples
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:SNMX
- CUSIP: N/A
- Web: www.senomyx.com
Capitalization:- Market Cap: $43.71 million
- Outstanding Shares: 47,514,000
Average Prices:- 50 Day Moving Avg: $0.71
- 200 Day Moving Avg: $0.79
- 52 Week Range: $0.56 - $2.92
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.13
- P/E Growth: -0.07
Sales & Book Value:- Annual Revenue: $19.56 million
- Price / Sales: 2.23
- Book Value: $0.26 per share
- Price / Book: 3.54
Profitability:- EBITDA: ($11,720,000.00)
- Net Margins: -63.38%
- Return on Equity: -85.22%
- Return on Assets: -54.58%
Debt:- Current Ratio: 3.74%
- Quick Ratio: 3.29%
Misc:- Average Volume: 214,583 shs.
- Beta: 1.06
- Short Ratio: 13.84
Frequently Asked Questions for Senomyx (NASDAQ:SNMX)
What is Senomyx's stock symbol?
Senomyx trades on the NASDAQ under the ticker symbol "SNMX."
How were Senomyx's earnings last quarter?
Senomyx, Inc. (NASDAQ:SNMX) issued its quarterly earnings results on Thursday, July, 27th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $4.87 million for the quarter, compared to the consensus estimate of $4.60 million. Senomyx had a negative return on equity of 85.22% and a negative net margin of 63.38%. Senomyx's revenue for the quarter was down 25.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.05) earnings per share. View Senomyx's Earnings History.
When will Senomyx make its next earnings announcement?
Where is Senomyx's stock going? Where will Senomyx's stock price be in 2017?
3 analysts have issued 1 year target prices for Senomyx's stock. Their predictions range from $2.00 to $2.00. On average, they expect Senomyx's share price to reach $2.00 in the next twelve months. View Analyst Ratings for Senomyx.
Who are some of Senomyx's key competitors?
Some companies that are related to Senomyx include Brainstorm Cell Therapeutics (BCLI), ArQule (ARQL), Tissue Regenix Group PLC (TRX), Vernalis plc (VER), Navidea Biopharmaceuticals (NAVB), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), CytRx Corporation (CYTR), OvaScience (OVAS), Prima BioMed Ltd (PBMD), ReNeuron Group Plc (RENE), Sunesis Pharmaceuticals (SNSS), Bio-Path Holdings (BPTH), Genocea Biosciences (GNCA), Fibrocell Science (FCSC), Abzena PLC (ABZA), Scancell Holdings Plc (SCLP) and Cleveland BioLabs (CBLI).
Who are Senomyx's key executives?
Senomyx's management team includes the folowing people:
- Kent Snyder, Chairman of the Board
- John W. Poyhonen, President, Chief Executive Officer, Director
- Sharon Wicker, Senior Vice President, Chief Commercial Development Officer
- David Humphrey, Vice President - Finance
- Daniel Edward Stebbins, Director
- Stephen A. Block Esq., Independent Director
- Mary Ann Gray Ph.D., Independent Director
- Michael E. Herman, Independent Director
- Christopher J. Twomey, Independent Director
How do I buy Senomyx stock?
Shares of Senomyx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Senomyx's stock price today?
One share of Senomyx stock can currently be purchased for approximately $0.92.
MarketBeat Community Rating for Senomyx (NASDAQ SNMX)MarketBeat's community ratings are surveys of what our community members think about Senomyx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Senomyx (NASDAQ:SNMX)Earnings History by Quarter for Senomyx (NASDAQ SNMX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/25/2017 | | | | | | | N/A |  |
| 7/27/2017 | Q2 2017 | ($0.07) | ($0.06) | $4.60 million | $4.87 million | View | N/A | |
| 4/28/2017 | Q1 2017 | ($0.08) | ($0.07) | $4.22 million | $4.47 million | View | N/A | |
| 3/2/2017 | Q4 2016 | ($0.09) | ($0.08) | $4.30 million | $4.20 million | View | Listen | |
| 10/27/2016 | Q316 | ($0.07) | ($0.05) | $5.36 million | $6.00 million | View | Listen | |
| 7/28/2016 | Q2 | ($0.06) | ($0.05) | $6.20 million | $6.60 million | View | Listen | |
| 4/28/2016 | Q1 | ($0.08) | ($0.05) | $5.78 million | $6.30 million | View | Listen | |
| 3/3/2016 | Q4 | ($0.07) | ($0.07) | $6.97 million | $6.27 million | View | Listen | |
| 10/29/2015 | Q315 | ($0.06) | ($0.05) | $7.62 million | $7.40 million | View | Listen | |
| 7/30/2015 | Q215 | ($0.10) | ($0.06) | $6.13 million | $6.20 million | View | Listen | |
| 4/30/2015 | Q115 | ($0.10) | ($0.11) | $5.86 million | $5.00 million | View | Listen | |
| 2/26/2015 | Q414 | ($0.11) | ($0.07) | $6.60 million | $6.30 million | View | Listen | |
| 11/6/2014 | Q314 | ($0.08) | ($0.10) | $7.90 million | $5.90 million | View | Listen | |
| 7/31/2014 | Q214 | ($0.08) | ($0.06) | $7.46 million | $7.34 million | View | Listen | |
| 5/1/2014 | Q114 | ($0.07) | ($0.05) | $7.60 million | $8.20 million | View | Listen | |
| 3/13/2014 | Q413 | ($0.06) | ($0.08) | $7.82 million | $7.41 million | View | Listen | |
| 11/12/2013 | Q313 | ($0.05) | ($0.09) | $8.19 million | $6.70 million | View | Listen | |
| 8/1/2013 | Q2 2013 | ($0.06) | ($0.06) | $7.64 million | $7.70 million | View | Listen | |
| 4/25/2013 | Q1 2013 | ($0.04) | ($0.07) | $8.45 million | $7.48 million | View | Listen | |
| 3/15/2013 | Q4 2012 | ($0.04) | ($0.06) | $8.39 million | $6.73 million | View | Listen | |
| 11/8/2012 | Q312 | ($0.07) | ($0.05) | $7.66 million | $7.90 million | View | N/A | |
| 8/7/2012 | | ($0.08) | ($0.08) | | | View | N/A | |
| 5/3/2012 | | ($0.05) | ($0.05) | | | View | N/A | |
| 3/1/2012 | | ($0.05) | ($0.04) | | | View | N/A | |
| 10/27/2011 | | ($0.08) | ($0.07) | | | View | N/A | |
| 8/5/2011 | | ($0.09) | ($0.08) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Senomyx (NASDAQ:SNMX)2017 EPS Consensus Estimate: ($0.25)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.07) | ($0.07) | ($0.07) |
| Q2 2017 | 1 | ($0.07) | ($0.07) | ($0.07) |
| Q3 2017 | 1 | ($0.06) | ($0.06) | ($0.06) |
| Q4 2017 | 1 | ($0.05) | ($0.05) | ($0.05) |
(Data provided by Zacks Investment Research)
Dividend History for Senomyx (NASDAQ:SNMX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Senomyx (NASDAQ:SNMX)Insider Ownership Percentage: 12.40%
Institutional Ownership Percentage: 28.86%
Insider Trades by Quarter for Senomyx (NASDAQ:SNMX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/24/2017 | Mary Ann Gray | Director | Buy | 10,000 | $1.00 | $10,000.00 | |
| 3/23/2017 | John Poyhonen | CEO | Buy | 50,000 | $0.98 | $49,000.00 | |
| 3/11/2015 | Sharon Wicker | SVP | Buy | 20,000 | $4.33 | $86,600.00 | |
| 10/1/2014 | Jay M Phd Short | Director | Sell | 7,500 | $8.16 | $61,200.00 | |
| 9/17/2014 | Donald Karanewsky | VP | Sell | 20,000 | $8.61 | $172,200.00 | |
| 9/11/2014 | Sharon Wicker | SVP | Sell | 40,525 | $9.12 | $369,588.00 | |
| 9/10/2014 | Antony E Rogers | CFO | Sell | 14,800 | $9.00 | $133,200.00 | |
| 9/10/2014 | Donald Karanewsky | VP | Sell | 20,000 | $8.50 | $170,000.00 | |
| 9/10/2014 | Sharon Wicker | SVP | Sell | 21,988 | $9.00 | $197,892.00 | |
| 6/19/2014 | Donald Karanewsky | VP | Sell | 20,000 | $8.86 | $177,200.00 | |
| 6/19/2014 | Sharon Wicker | SVP | Sell | 50,100 | $9.12 | $456,912.00 | |
| 6/13/2014 | Antony E Rogers | CFO | Sell | 2,997 | $8.41 | $25,204.77 | |
| 6/12/2014 | Donald Karanewsky | VP | Sell | 20,000 | $8.50 | $170,000.00 | |
| 6/10/2014 | Stephen A Block | Director | Sell | 28,750 | $8.21 | $236,037.50 | |
| 6/5/2014 | John Poyhonen | CEO | Sell | 37,600 | $8.00 | $300,800.00 | |
| 5/9/2014 | Michael E Herman | Director | Buy | 14,000 | $6.47 | $90,580.00 | |
| 4/17/2014 | Donald Karanewsky | VP | Sell | 20,000 | $8.72 | $174,400.00 | |
| 4/11/2014 | Kent Snyder | Director | Sell | 45,688 | $9.88 | $451,397.44 | |
| 4/9/2014 | Kent Snyder | Director | Sell | 45,688 | $10.60 | $484,292.80 | |
| 4/7/2014 | Kent Snyder | Director | Sell | 68,532 | $11.13 | $762,761.16 | |
| 4/7/2014 | Sharon Wicker | SVP | Sell | 31,154 | $10.61 | $330,543.94 | |
| 4/2/2014 | Kent Snyder | Director | Sell | 68,532 | $11.06 | $757,963.92 | |
| 4/1/2014 | Jay M Phd Short | Director | Sell | 11,590 | $10.66 | $123,549.40 | |
| 3/17/2014 | Michael E Herman | Director | Buy | 33,000 | $10.09 | $332,970.00 | |
| 1/14/2014 | Jay M Phd Short | Director | Sell | 4,090 | $6.50 | $26,585.00 | |
| 12/23/2013 | Sharon Wicker | SVP | Sell | 13,749 | $4.80 | $65,995.20 | |
| 12/20/2013 | Sharon Wicker | SVP | Sell | 38,565 | $4.71 | $181,641.15 | |
| 12/3/2013 | Sharon Wicker | SVP | Sell | 91,196 | $4.24 | $386,671.04 | |
| 11/25/2013 | Sharon Wicker | SVP | Sell | 12,269 | $4.21 | $51,652.49 | |
(Data available from 1/1/2013 forward)
Headline Trends for Senomyx (NASDAQ:SNMX)
Latest Headlines for Senomyx (NASDAQ:SNMX)
| Source: |
|
Loading headlines, please wait.
Senomyx (SNMX) Chart for Sunday, October, 22, 2017
